Canada’s Drug Agency is pleased to announce the successful applicants from our 2024 Request for Proposals (RFP) to support the enhancement of rare disease registries in Canada. The awarded rare disease registries span diverse disease areas and will undertake varied improvement initiatives, all with the goal of generating high quality and fit-for-purpose data that can be used to help answer regulatory and reimbursement questions related to drugs for rare diseases.

Drug sponsors can now request a flexible service through our Scientific Advice program that can include a shorter time frame.

For Scientific Advice after pivotal trials designs are finalized, the program now offers more timely advice on anticipated key uncertainties or evidence gaps based on the clinical evidence plan. This flexible service can be completed with a lower fee in as little as 4 weeks.